IDO Monoclonal Antibody (eyedio), PE-Cyanine7, eBioscience™, Invitrogen™

Description

• This eyedio MAb reacts with human indoleamine-2,3-dioxygenase (IDO, INDO, IDO1), an intracellular enzyme that catalyzes the degradation of tryptophan to kynurenines
• IDO is expressed in a wide variety of tissues and cells, including macrophages, plasmacytoid dendritic cells, and several cell lines
• IDO can be induced in many different cell types by IFN gamma or other inflammatory stimuli
• Expression of IDO in antigen presenting cells and tumors is thought to mediate immune suppression through depletion of this essential amino acid and/or by the creation of tryptophan metabolites that cause apoptosis of T cells and induction of regulatory T cells
• IDO1 is an intracellular heme-containing enzyme that catalyzes the oxidative cleavage of the indole ring of several important regulatory molecules like tryptophan, serotonin, and melatonin
• By doing this, IDO1 initiates the production of biologically active metabolites, commonly referred to as kynurenines
• IDO1 is widely expressed in a variety of human tissues as well as in macrophages and dendritic cells (DCs)
• In inflammation, interferons (IFNs) act on specific receptors to trigger IDO1 induction
• The production of IFN-gamma and induction of IDO1 represent important antimicrobial mechanisms
• Degradation and depletion of tryptophan by IDO1 inhibits the growth of viruses, bacteria and parasites
• Furthermore, IDO1 plays a complex and crucial role in immunoregulation during infection, pregnancy, autoimmunity, transplantation, and neoplasia.